Parabilis Medicines Inc experienced an uptick in its stock price in early trading after several directors and a major investor acquired common shares and recorded conversions of preferred stock into common stock following the company's initial public offering.
According to filings with the Securities and Exchange Commission, director Alan Sebulsky purchased 12,500 shares of Parabilis common stock on June 11 at $20 per share. The purchase was made indirectly through Apothecary Capital LLC, where Sebulsky is listed as the managing member.
Also on June 11, RA Capital Management, L.P. executed purchases on behalf of affiliated funds. RA Capital Healthcare Fund, L.P. purchased 19,728,353 shares at $20 per share, while RA Capital Nexus Fund III, L.P. bought 1,460,397 shares at the same price. After these transactions, RA Capital’s funds collectively hold 28,933,371 shares.
These buy transactions took place in the days following Parabilis’s initial public offering, which closed on June 9. In addition to the purchases, several insiders received common stock through automatic conversions of preferred stock that occurred directly prior to the IPO closing.
Director Alexis Borisy received 105,414 shares through the conversion of Series F Preferred Stock. Director Edward M. Fitzgerald was issued 14,688 shares through conversions of Series B, C, and F Preferred Stock. RA Capital Management’s funds also received shares via automatic conversions: 6,556,740 shares from Series E Preferred Stock and 1,187,881 shares from Series F Preferred Stock.
Market participants typically view insider buying and post-IPO conversions as signals of insiders' confidence in a company’s prospects. In this instance, the disclosed transactions were associated with the recent completion of the initial public offering and related preferred-to-common conversions.
Parabilis Medicines is headquartered in Cambridge, Massachusetts.
Context and timing
The share purchases and automatic conversions were recorded on June 11, immediately following the IPO close on June 9. The filings describe both direct purchases at $20 per share and multiple automatic conversions of various series of preferred stock into common shares.
Regulatory disclosure
All transactions referenced here were disclosed in Form 4 filings with the Securities and Exchange Commission, which detail the number of shares acquired, the price per share, and the entities or funds through which purchases were made.
Observed market reaction
Shares of Parabilis rose in premarket trading on the day the filings were made public, reflecting market attention to the insider activity immediately following the IPO.